Chai Discovery Raises Series B

Chai, a biotech firm backed by OpenAI, has secured $130 million in Series B funding, valuing the company at $1.3 billion. Chai is focused on developing foundation models designed for drug discovery. These models aim to predict interactions between molecules, with the goal of repurposing them for therapeutic applications.

The company's approach involves creating AI models capable of understanding and predicting how different molecules will interact. This technology could significantly accelerate the drug discovery process by identifying promising candidates and potential treatments more efficiently. The investment will likely fuel further development and refinement of these AI-driven models.

By leveraging AI, Chai hopes to transform how new drugs are discovered and developed, potentially leading to faster and more effective treatments for a variety of diseases. The company is at the forefront of applying advanced machine learning techniques to solve complex problems in the biotech industry.